bleeding episodes and 58 surgical procedures. [5] [6] [7] In 2011, two additional registries, which were designed in part to capture post-marketing surveillance data around the use of recombinant factor VIIa (rFVIIa) closed, capping a multiyear effort by dedicated hematologists around the world to track treatment of Glanzmann's Thrombasthenia and congenital Factor VII (FVII) Deficiency, irrespective of treatment product.
Initiated in 2006, the Glanzmann's Thrombasthenia Registry (GTR) captured data on 218 patients with Glanzmann's Thrombasthenia from 45 sites in 15 countries with 1073 admissions for 870 bleeding episodes and 204 surgical procedures. 8 The Seven Treatment Evaluation Registry (STER) captured data on 75 patients with FVII deficiency from 15 countries with 101 bleeding events. 9 STER also captured data on 38 patients with 38 surgical procedures, along with data on 34 patients treated with routine FVII replacement. 10, 11 There certainly is the temptation to move right from the "need" to capture data about a rare disorder to choosing a registry or electronic medical record platform. Recent approval of plasma derived replacement for fibrinogen and factor XIII (FXIII), as well as a recombinant FXIII concentrate highlight the need for accumulating such post-approval data.
One of the key issues around the accumulation of clinical or registry/trial data is that the data would have little or no utility for either clinical management or scientific research without assurances that the laboratory diagnosis and monitoring assays of the RBDs were accurate and consistent. Many of the participating institutions in clinical studies, registries, and database
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This article is protected by copyright. It has been suggested that proteomic and genomic technologies may become the focus in the analysis of patients with inherited platelet disorders and that whole exome or whole genome sequencing may become a first line to identify the molecular basis of rare diseases. 19 The BRIDGE consortium in the United Kingdom aims to discover the genetic basis of the inherited Rare Diseases and the Bleeding and Platelet Diseases substudy specifically aims to develop and validate a sensitive Next Generation Sequencing-based test to detect clinically relevant variants in bleeding and platelet diseases, and in order to do so, aims to first identify the genetic basis of rare bleeding and platelet disease. 20, 21 The BRIDGE study is using a central BRIDGE Sample
Intake Laboratory to collect and sequence all DNA samples, including samples from other BRIDGE studies in pulmonary arterial hypertension, primary immune disorders, steroid resistant nephrotic syndrome, and Ehlers-Danlos syndromes. 21 Also in the United Kingdom, through collaboration with the ISTH-SSC, the National Institute for Biological Standards and Control (NIBSC) provides plasma and coagulation factor standards calibrated by laboratories of SSC-associated investigators. 22 NIBSC is a World Health Organization (WHO) international laboratory for biological standards and prepares, evaluates and distributes International Biological Standards. 23 In addition, NIBSC is responsible for regulatory testing of biological medicines in the European Union. 23 The presence of such a regulatory body allows for strict oversight of the laboratories which use these assays for the 
This article is protected by copyright. All rights reserved Improvements Amendments (CLIA). CAP and CLIA certifications are however voluntary and are for standardized tests only. They are not available for tests required for the diagnosis of RBD such as FXIII deficiency. They also do not mandate a specific assay or assay platform and therefore allow for great inter-laboratory variability. Research testing is allowed by CLIA but it does not allow the laboratory to report patient specific results and therefore cannot be used for diagnostic purposes. The UK also has the advantage of a significantly smaller geographic area allowing limited number of laboratories to provide services. Unfortunately such consolidation of services is not possible to serve the wide spread needs of the USA and North America. Also unique to the USA is that the CMS does not guarantee that laboratory workups will be reimbursed for, through the health mechanisms available in the USA.
Children's Oncology Group (COG) provides perhaps some guidance on the ability to implement a national central lab resource in the US. COG is a National Cancer Institute (NCI) supported clinical trials group uniting more than 8,000 experts at more than 200 children's hospitals, universities and cancer centers across North America, Australia, New Zealand and Europe. More than 90% of the 13,500 children and adolescents diagnosed with cancer in the US each year are treated within the network, and there are at any time about 100 active trials. COG has complex risk classification systems that are used to deliver risk-stratified therapy for many pediatric cancers, and classification of patients is based on biological, clinical, and genomic data obtained and entered automatically from both treating institutions and central laboratories. 24 While there is overlap between the hematology community (including the hemophilia treatment center network) and the oncology community that already is accustomed to having central laboratory functions under federal (NCI) funding, autonomy and practical logistical considerations might limit applicability of a central lab function in hematology and especially coagulation testing. Establishment of a central lab would require the transportation of specimens to the central laboratory. In the study of platelet disorders which forms a significant proportion of RBD's, it is not possible to transport the specimen (whole blood or platelet rich plasma) as platelet lysis during transportation is inevitable and would make the sample useless. Further, many of the specialty coagulation laboratories already have CAP-CLIA certification and can perform many of these assays. Regional/local differences in insurance coverage might limit the ability for payor funding of confirmatory tests, most of which may be classified as RUO.
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Assuming funding wasn't an issue, would such local/regional/national labs be willing to send samples to another academic institution or commercial laboratory that was designed as the central lab? Given some labs may have specific expertise in a particular RBD, either through epidemiologic differences or by serving central lab roles in compassionate use programs in
RBDs (e.g. congenital FXIII deficiency), should there be more than one central lab or specifically a central lab designed by disease?
So, if for RBDs a centralized RBD laboratory function were felt to be advantageous in the US or more broadly in North America, how could this be developed and implemented? Some key points are illustrated below:
• All key stakeholders need to be involved in the discussions including federal entities, professional societies, the hemophilia and RBD treatment center network, specialty coagulation laboratories, and patient advocacy organizations ( Table 1 ).
• Agreement would need to reached as to the scope of specific testing available, but likely including uncommon coagulation or platelet function tests, factor assays including testing to determine inhibitors (Bethesda-type assays), and perhaps genotyping.
• There would need to be consensus on a more standardized diagnostic approach, perhaps following ISTH-SSC or other guidelines where available and applicable.
• The allocation of specific diseases/tests to several laboratories or development/engagement of a single central laboratory would need to be determined.
• The funding for such a project would need to be secured, whether initially as a pilot (specific tests or diseases) or as a more complete project.
The role of pharmaceutical companies in such an RBD diagnostic laboratory network also deserves some consideration. Certainly, as manufacturers for products, companies are responsible for pre-approval clinical trials and post-approval surveillance of patients to determine safety and efficacy. This implicitly requires accurate diagnosis and the ability to monitor patients treated outside of prospective trials that end with a product's launch. It would be preferable for companies to assure the central lab's role throughout their clinical development,
This article is protected by copyright. All rights reserved anticipate that other pharmaceutical members will follow suit.
There could be additional benefits to considering a centralized laboratory for uncommon RBD assays.
• Validation studies to support FDA approval of the assays would be much easier if a single central laboratory or group of laboratories could pool dozens of samples from across the US, and thus support uniform insurance coverage. Availability of approved tests would allow for more specific diagnostic and monitoring recommendations in package labelling.
• Cost-efficiencies can be achieved by pooling many samples to run assays together. For example, reagent kits for ELISA assays where available (e.g. FXIII A 2 , B 2 and A 2 B 2 antigen) 13 can be costly if only used for one patient.
• In association with refinements to ICD-9CM/ICD-10 to support individual codes for each rare disorder (currently pooled under 286.4/D68.2 for other clotting factor deficiencies as well as other codes for congenital and acquired bleeding disorders), data from a central laboratory would help with epidemiologic study of these rare diseases.
• By identifying the experts in each of these RBDs in this process, it would also connect the physician caring for the patients with RBDs to the experts in the field providing better standardization of care.
In the "real world" of medical care outside of the clinical research environment, there is a critical need for health care practitioners to recognize and diagnose bleeding disorders in an efficient and timely manner. Research has indicated that the physicians who encounter patients with RBDs often overlook RBDs as a differential diagnosis and do not approach the laboratory confirmation in an adequate, targeted, or cost efficient manner. Further, they may not receive insightful guidance from their non-clinically oriented coagulation laboratory directors. In an effort to assist healthcare practitioners in the diagnosis of bleeding disorders and to ultimately facilitate appropriate referrals to knowledgeable hematologists, one pharmaceutical company (Novo Nordisk) has developed a "user friendly" educational resource around diagnostic assays, the Coags Uncomplicated iPhone/Android/web application. 25 As part of the application, the Lab
Value Analyzer first allows healthcare practitioners to screen for medication-related abnormalities, then pattern-matches lab values entered with disease profiles and lists potentially matching diagnoses. The Diagnostic Algorithm provides a resource to help healthcare practitioners in considering appropriate additional lab tests.
When a RBD is suspected in an acute bleeding emergency, the central laboratory probably will not allow relevant patient management in real time. These situations are often managed with traditional therapies such as Cryoprecipitate and FFP prior to establishment of the diagnosis .
The diagnostic samples are frequently obtained prior to this intervention and would be the target of the " central laboratory" to facilitate the establishment of the correct diagnosis which can then lead to more targeted intervention.
In this call to action and to address these concerns, objective data need to be gathered to survey the coagulation laboratories around the US and Canada (in commercial, tertiary care hospitals, and research laboratories) to determine current capabilities and to identify unmet needs. It is possible that this could lead to improved accessibility to laboratories established by a consortium of the FDA, industry, professional advocacy groups (ISTH-SSC, THSNA, HTRS), NIH, university research laboratories, and the CDC.
With adoption of this type of central laboratory model for RBDs, the needs of the stakeholders and the patient community can be served efficiently (both from the healthcare and fiscal
This article is protected by copyright. All rights reserved perspectives). Third party payers also have an obligation to ensure that patients have received the correct diagnosis and treatment and therefore would be an equal stakeholder in this effort.
Further, availability of accurate, reproducible, and reliable laboratory data would support public health and product surveillance, clinical research, and quality improvement initiatives in care of patients with RBDs. 
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